Lakewood-Amedex Biotherapeutics, Inc. (LABT) News
Track canonical SquawkNews coverage tagged to LABT, Lakewood-Amedex Biotherapeutics, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 12 indexed stories across 9 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Lakewood-Amedex Biotherapeutics Inc. (LABT) Starts Phase 2a Dosing for Nu-3; Data Expected Q1 2027
Lakewood-Amedex Biotherapeutics dosed the first patient in a Phase 2a trial of Nu-3 for mildly infected diabetic foot ulcers. The study tests 2%, 5%, and 10% gel concentrations, with topline data expected in Q1 2027.Mate
NEWS | Sep 24, 2026, 12:03 PM UTC
L
LABT - Lakewood-Amedex Biotherapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of Nu-3 for Infected Diabetic Foot Ulcers
LABT - Lakewood-Amedex Biotherapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of Nu-3 for Infected Diabetic Foot Ulcers
NEWS | Sep 24, 2026, 12:02 PM UTC
L
Lakewood-Amedex Biotherapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of Nu-3 for Infected Diabetic Foot Ulcers
Initiation of patient dosing marks significant clinical development milestone for Nu-3 and Lakewood-Amedex Biotherapeutics' proprietary Bisphosphocin® antimicrobial platformTopline data expected in the first quarter of 2
NEWS | Sep 24, 2026, 12:02 PM UTC
L
LABT - Lakewood-Amedex Biotherapeutics CEO Issues Letter to Shareholders Highlighting Transformational Progress and Outlook for Nu-3
LABT - Lakewood-Amedex Biotherapeutics CEO Issues Letter to Shareholders Highlighting Transformational Progress and Outlook for Nu-3
NEWS | Sep 21, 2026, 12:02 PM UTC
L
LABT - Lakewood-Amedex Biotherapeutics Announces IRB Approval and Clinical Site Readiness to Initiate Phase 2a Clinical Trial of Nu-3 for the Treatment of Infected Diabetic Foot Ulcers
LABT - Lakewood-Amedex Biotherapeutics Announces IRB Approval and Clinical Site Readiness to Initiate Phase 2a Clinical Trial of Nu-3 for the Treatment of Infected Diabetic Foot Ulcers
NEWS | Sep 18, 2026, 12:16 PM UTC
L
LABT to present at H.C. Wainwright 28th annual conference
Lakewood-Amedex Biotherapeutics (LABT) will present at the H.C. Wainwright 28th Annual Global Investment Conference.
EQUITY | Sep 08, 2026, 12:02 PM UTC
H
Crude Oil Gains 2%; GE Vernova Shares Fall After Q2 Earnings
U.S. stocks traded mostly higher midway through trading, with the Dow Jones index gaining more than 200 points on Wednesday. The Dow traded up 0.40% to 52,432.64 while the NASDAQ declined 0.01% to 25,834.80. The S&P 500
MACRO | Jul 22, 2026, 04:09 PM UTC
H
Lakewood-Amedex supports reintroduction of PASTEUR act
Lakewood-Amedex Biotherapeutics announced its support for the reintroduction of the bipartisan Pioneering Antimicrobial Subscriptions to End Upsurging Resistance, PASTEUR, Act, legislation designed to "encourage" the dev
EQUITY | Jul 07, 2026, 12:10 PM UTC
M
12 Health Care Stocks Move
Twelve health care stocks are moving in Thursday's after-market session, with Shuttle Pharmaceuticals and INVO Fertility among the gainers and Creative Medical Tech and Catheter Precision among the losers
EQUITY | Jun 25, 2026, 09:05 PM UTC
L
LABT Appoints Study Chair
Lakewood-Amedex Biotherapeutics appoints Dr. David G. Armstrong as study chair for Phase 2a trial of Nu-3 in infected diabetic foot ulcers
EQUITY | Jun 25, 2026, 12:03 PM UTC
M
LABT Secures Patent
Lakewood-Amedex Biotherapeutics secures composition of matter patent for new Bisphosphocin compounds
EQUITY | Jun 22, 2026, 12:03 PM UTC